Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are at least 18 years old and are willing to give your consent to take part
- You are relatively active and able to carry out daily activities with little to no limitation (this is measured on a standard scale called ECOG — confirm with trial site if unsure where you fall)
- You have been diagnosed with a solid tumour cancer that has spread locally or to other parts of the body, and your tumour has a specific genetic change called "KRAS G12V mutation"
- You have already received standard treatment for your cancer type, but your cancer got worse during that treatment or you were unable to tolerate it
- Your cancer can be measured on a scan using standard methods (called RECIST v1.1 — confirm with trial site)
- Your bone marrow, liver, kidneys, and blood clotting are all working well enough to take part
- You are able to swallow and take medication by mouth
Who may not be able to join:
- Your cancer started in the brain or spinal cord
- You have previously had treatment that specifically targeted the KRAS G12V mutation or any direct RAS-targeted therapy
- You have any condition that might affect your ability to swallow, digest, or absorb the study drug (confirm with trial site)
- You have had major surgery within 28 days before starting the study drug
- You are unable or unwilling to attend the required study visits or follow the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-844-2-REVMED
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with adverse events (AEs); Changes in vital signs; Changes in electrocardiogram (ECG) test values; Changes in clinical laboratory test values; Dose Limiting Toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.